Healthcare Times Utah: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Times Utah.

November 2025

Mo	Tu	We	Th	Fr	Sa	Su
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

December 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

January 2026

Mo	Tu	We	Th	Fr	Sa	Su
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Press releases published on January 30, 2026

an hour ago

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

GlobeNewswire

4 hours ago

Dr. Christina Rahm and Clayton Thomas of The ROOT Brands Attend World Economic Forum Annual Meeting 2026 in Davos

GlobeNewswire

4 hours ago

Dr. Linette Williamson Expands Integrative Medicine Services in Encinitas With Physician-Supervised Ozone Sauna Therapy

GlobeNewswire

4 hours ago

CrazyBulk: SARM Alternatives for Bulking, Strength and Performance or Just Hype?

GlobeNewswire

5 hours ago

OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting

GlobeNewswire

5 hours ago

Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma

GlobeNewswire

6 hours ago

Global Virus Network Statement on Nipah Virus Outbreak

GlobeNewswire

7 hours ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

GlobeNewswire

7 hours ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

GlobeNewswire

7 hours ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

GlobeNewswire

7 hours ago

Global Drug Device Combination Products Market to Reach USD 379.17 Billion by 2030 | MarketsandMarkets™

GlobeNewswire

7 hours ago

Standard BioTools Completes Sale of SomaLogic to Illumina

GlobeNewswire

7 hours ago

Scilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets

GlobeNewswire

7 hours ago

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

GlobeNewswire

8 hours ago

ALX Oncology Announces Pricing of Underwritten Offering

GlobeNewswire

8 hours ago

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

GlobeNewswire

8 hours ago

Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value

GlobeNewswire

8 hours ago

New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer

GlobeNewswire

8 hours ago

IO Biotech Provides Corporate Update

GlobeNewswire

8 hours ago

Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq

GlobeNewswire